Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
13.16 USD | -0.83% | -3.99% | -11.80% |
05-14 | Oppenheimer Lowers UroGen Pharma Price Target to $32 From $34, Maintains Outperform Rating | MT |
05-13 | Transcript : UroGen Pharma Ltd., Q1 2024 Earnings Call, May 13, 2024 |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
SubscribeEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.80% | 479M | |
+10.09% | 114B | |
+12.93% | 107B | |
-5.34% | 22.22B | |
-0.67% | 21.28B | |
-4.64% | 18.8B | |
-6.58% | 17.51B | |
-39.36% | 17.17B | |
+6.88% | 14.14B | |
+34.96% | 12.2B |
- Stock Market
- Equities
- URGN Stock
- News UroGen Pharma Ltd.
- Transcript : UroGen Pharma Ltd. - Analyst/Investor Day